AMOR-1

Phase 2Small molecule

AAmorphical Ltd.

AMOR-1 is one of 7 small molecule programs targeting Hypoparathyroidism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

2 2

Calciferol

Rocaltrol

Calcium

1 5

AMOR-1

AAmorphical Ltd.

Phase 2

1 6

EXT608

EExtend Biosciences Inc.

Phase 2

1 7

Yorvipath

Ascendis Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hypoparathyroidism

NCT06547151

Clinical

Trials by Indication[1]

Hypoparathyroidism1 trial

A Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated With Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults.

Active, not recruiting·AAmorphical Ltd.·Phase 2·NCT06547151·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMOR-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMOR-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMOR-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amorphical Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAmorphical Ltd.

AMOR-1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News